Policy | November 11, 2025
Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
